| Literature DB >> 30760321 |
Irit Meivar-Levy1,2, Fatima Zoabi3,4, Gil Nardini5, Eugenia Manevitz-Mendelson6, Gil S Leichner6, Oranit Zadok3, Michael Gurevich7, Eytan Mor7, Simona Dima8,9,10, Irinel Popescu8,9,10, Aviv Barzilai4,6, Sarah Ferber3,8,4, Shoshana Greenberger4,6.
Abstract
BACKGROUND: Insulin-dependent diabetes is a multifactorial disorder that could be theoretically cured by functional pancreatic islets and insulin-producing cell (IPC) implantation. Regenerative medicine approaches include the potential for growing tissues and organs in the laboratory and transplanting them when the body cannot heal itself. However, several obstacles remain to be overcome in order to bring regenerative medicine approach for diabetes closer to its clinical implementation; the cells generated in vitro are typically of heterogenic and immature nature and the site of implantation should be readily vascularized for the implanted cells to survive in vivo. The present study addresses these two limitations by analyzing the effect of co-implanting IPCs with vasculature promoting cells in an accessible site such as subcutaneous. Secondly, it analyzes the effects of reconstituting the in vivo environment in vitro on the maturation and function of insulin-producing cells.Entities:
Keywords: Bone marrow–derived mesenchymal stem cells; Endothelial colony-forming cells; Insulin-producing cells; Pancreatic transcription factors; Transdifferentiation; Vasculature
Year: 2019 PMID: 30760321 PMCID: PMC6373031 DOI: 10.1186/s13287-019-1157-5
Source DB: PubMed Journal: Stem Cell Res Ther ISSN: 1757-6512 Impact factor: 6.832
Fig. 1Co-implantation of MSCs, ECFCs, and IPCs promotes vascularization of the implants in vivo. SCID-beige mice were implanted subcutaneously with cells mixed with Matrigel, with four implants containing IPCs/ ECFCs/MSCs (1/1/1) implanted in each mouse (n = 8) or control implants of only IPCs (n = 6) as illustrated in a. b The implants were retrieved 4 to 8 weeks post implantation. c The implants were stained with H&E and anti-human CD31. Panels showing representative implants. Scale bar, 50 μm. d Microvessel density (MVD) was assessed by counting CD31-positive vessels. Values reported for each experimental condition correspond to the average MVD value ± standard error of the mean (SEM) obtained from n > 6 for 4 and 8 weeks
Fig. 2Human microvessels promote the survival and function of IPCs in vivo. a The implants retrieved after 4 weeks of implantation were stained using anti-HLA (a, upper panel) and anti-human insulin (a, lower panel) in the IPC/ECFC/MSC implants and the IPC implants. b Quantification of HLA-positive cells was done by counting cells in random five × 40 fields from each implant. Values reported for each experimental condition correspond to the average cell number ± standard error of the mean (SEM) obtained from n > 6 for 4 and 8 weeks, *P value < 0.05. c The IPC/ECFC/MSC implants were double stained for insulin (green) and glucagon (red). d Serum human c-peptide upon glucose stimulation was measured at 2, 4, and 8 weeks post implantation. The results are average and standard error (SE) for three to eight mice per group, at each time point, *P value < 0.05
Fig. 3ECFC and MSC co-culturing in the Transwell® system promotes pTF induced liver-to-pancreas transdifferentiation in vitro. Induced IPCs were cultured on the bottom of the Transwell®; inserts were plated with ECFCs or MSCs or ECFCs + MSCs (1:1 ratio) or with IPCs as a control, as illustrated in a. After 3 days, the transdifferentiation efficiency of the cells was measured, as seen in b: the transcript levels of the pancreatic-specific genes are presented as average and SE for increases in the above cells treated with pTFs only, cultured in a regular 12 wells/plate (TC plate) and normalized to β-ACTIN levels, *P value < 0.05 and **P value < 0.01, respectively. c Glucose-regulated insulin secretion was measured using a specific human RIA kit (DPC). The secretion in the cells that were cultured in the Transwell® system was compared to cells cultured in a regular 12 wells/plate (TC plate). Results are presented as average and SE, n ≥ 12 from four independent repeats in different donors, *P value < 0.01 compared to cells treated with pTFs only, cultured in a regular TC plate treatment. The labeling below the graphs indicates the cell type cultured in the inserts of the Transwell® system
Fig. 4Co-culturing ECFCs and MSCs promotes the expression of specific growth factors. MSCs and ECFCs were cultured separately or co-cultured at a 1:1 ratio. Five days later, cells from the co-culture were immune-separated. CD31 (a), CTGF (b), and ACTIVIN-A (c) transcript levels were analyzed. The results were normalized to GAPDH gene expression. The results are presented as average and SE, n = 2 independent repeats in triplicates, with *P value < 0.01 compared to human skin fibroblasts serving as a negative control
Fig. 5Conditioned media promotes pancreatic differentiation during the TD process. Conditioned media was collected after 48 h of co-culturing the ECFCs and MSCs (1:1 ratio). The media was added to the liver cell that was undergoing transdifferentiation either when fresh or after being heated to 56 °C (1:1 ratio with TD media), as illustrated in a. b The IPCs were analyzed for glucose-regulated insulin secretion. Insulin levels were analyzed using a specific human RIA kit (DPC) and compared to cells cultured in TD media (fresh or heated). Results are presented as average and SE for increases above secretion at low glucose in TD media, n ≥ 8 from three independent repeats in different donors, *P value < 0.01 compared to control treatment (c–e). The conditioned media was added (1:1 ratio with TD media) at day 1 or day 3 of the TD process, and the pancreatic phenotype was analyzed by specific pancreatic gene expression (c, d) and glucose-induced insulin secretion (e). Transcript levels of the indicated genes are presented as average and SE for increases above cells treated with pTFs alone and normalized to β-actin levels. N = 3–4 independent repeats in different donors, *P value < 0.01 and **P value < 0.05 compared to control treatment. Insulin levels were analyzed using a specific human ELISA kit (ALPCO) and compared to cells cultured in TD media. The results are presented as average and SE normalized to cell number, n ≥ 8 from three different experiments, *P < 0.01 and **P < 0.05 compared to control treatment